A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab
Gerardo Rosati(Ospedale San Carlo), Stefano Cascinu(Vita-Salute San Raffaele University), Rossana Berardi(Marche Polytechnic University), Monica Giordano(Ospedale Sant'Anna), L. Frontini, Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Francesco Ferraù(Université Paris-Sud), Sara Lonardi(Istituto Oncologico Veneto), Domenico Corsi(Ospedale San Carlo), Adriana Romiti(Sapienza University of Rome), Guglielmo Nasti, Roberto Labianca(Ospedale Papa Giovanni XXIII), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Vincenzo Rosario Iaffaioli, Massimo Aglietta(Candiolo Cancer Institute), Valentina Angela Marsico(Istituto Oncologico Veneto), Francesca Galli(University of Modena and Reggio Emilia)
Cited by 2
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k